Grifols Launches FESILTY™ (fibrinogen, human-chmt) in the U.S.

BARCELONA, Spain, June 15, 2026 (GLOBE NEWSWIRE) -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading producer of plasma-derived medicines, today announced the U.S. launch of its new fibrinogen concentrate. Approved by the U.S. Food and Drug Administration in December for the treatment of acute bleeding episodes in pediatric and adult patients with congenital fibrinogen deficiency (CFD), including hypo- or afibrinogenemia, FESILTY™ (fibrinogen, human-chmt) is now available in the U.S. FESILTY is not indicated for dysfibrinogenemia.

GlobeNewsWire • Jun 15, 2026

Grifols: Plasma Self-Sufficiency Is The Mispriced Catalyst

Grifols is transitioning from a leveraged recovery story to a strategic plasma infrastructure leader with global scale and supply security advantages. GRFS trades at a significant valuation discount—forward P/E of 8.42x and price/cash flow of 4.76x—despite robust EBITDA, margin expansion, and improving free cash flow. Recent refinancing pushes major debt maturities to 2028; management guides for 2026 EBITDA margins of at least 25% and €500–€575 million free cash flow pre-dividends.

Seeking Alpha • Jun 4, 2026

Grifols, S.A. (GIKLY) Q1 2026 Earnings Call Transcript

Grifols, S.A. (GIKLY) Q1 2026 Earnings Call Transcript

Seeking Alpha • May 9, 2026

Ban Grifols and return plasma collection to Canadian Blood Services and Héma-Québec, say health care advocates

OTTAWA, March 30, 2026 (GLOBE NEWSWIRE) -- Proponents of public universal health care across Canada are calling for the closure of Grifols facilities in the wake of two deaths in Winnipeg of people who sold their plasma to the giant multinational. A third person is suing the hugely profitable Grifols for kidney damage from a plasma sale. Health Canada also reports non-compliance at four other Grifols sites.

GlobeNewsWire • Mar 30, 2026

Grifols approves IPO of its US biopharma business

Healthcare ​company Grifols ‌said ​on ​Tuesday it ⁠has ​approved ​a U.S. ​initial ​public offering of ‌its ⁠U.S. biopharma ​business.

Reuters • Mar 24, 2026

Grifols Shares Results From its Chronos Platform Identifying Early Molecular Changes Associated with Parkinson's Disease

BARCELONA, Spain, March 17, 2026 (GLOBE NEWSWIRE) -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading producer of plasma-derived medicines, today shared proof-of-concept data from its Chronos-PD program, demonstrating that biological changes in individuals with Parkinson's disease (PD) occur more than a decade before clinical diagnosis, with potential future implications for early detection and intervention.

GlobeNewsWire • Mar 17, 2026

Health Coalition demands disclosures & end to Grifols' for-profit blood plasma contract following reports of deaths, harm, non-compliance

TORONTO, March 13, 2026 (GLOBE NEWSWIRE) -- The Ontario and Manitoba Health Coalitions held a press conference this morning to respond to a  report from CBC  about two patients who died in Winnipeg after having their blood plasma harvested at centres owned by for-profit pharmaceutical corporation Grifols.  Another report followed, of a man who is suing , alleging kidney damage from equipment failure while having his plasma harvested at a Grifols centre. The Alberta Friends of Medicare  revealed that Grifols has been found non-compliant  with serious breaches at their Calgary centre. Inspection reports from Health Canada show that four Grifols centres have been found non-compliant in Calgary , Alberta; St. John , New Brunswick; and Regina and Saskatoon , Saskatchewan.

GlobeNewsWire • Mar 13, 2026

Media Advisory: Press Conference Regarding Tragic Deaths After Plasma Harvesting at Grifols' Sites

WINNIPEG, Manitoba and TORONTO, March 12, 2026 (GLOBE NEWSWIRE) -- What: Spokespeople from the Manitoba Health Coalition and Ontario Health Coalition will respond to the sad news of two deaths of paid “donors” at for-profit plasma collection facilities owned by pharma giant Grifols. The Coalitions have long raised warnings about safety and the ownership and control of the blood system.

GlobeNewsWire • Mar 12, 2026

Grifols: I'm Very Happy To Add In 2026

Grifols is a global leader in blood plasma, now rated 'BUY' with a €20/share PT and $23/share ADR target. GRFS has delivered €450M in cost savings, 150%+ net profit growth, and FCF exceeding guidance, with leverage down to 4.2x. Despite a BB- rating, improved fundamentals, dividend reinstatement, and forecasted 20–25% annual growth support a strong risk/reward profile.

Seeking Alpha • Mar 12, 2026

Grifols doubles net profit in 2025, driven by revenues

Spanish drugmaker Grifols reported on Thursday a net profit of 402 million euros ($473.96 million) for 2025, more than double what it recorded the previous year, driven by revenues of 7.5 billion euros, up 7% from a year earlier.

Reuters • Feb 26, 2026